MassMutual Private Wealth & Trust’s Crinetics Pharmaceuticals CRNX Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.45K	Sell	199 -25	-11%	-$929	﹤0.01%	1525
2026 Q1	$8.14K	Buy	224 +23	+11%	+$1.03K	﹤0.01%	1448
2025 Q4	$9.36K	Sell	201 -57	-22%	-$2.54K	﹤0.01%	1419
2025 Q3	$10.7K	Buy	+258	New	+$8.25K	﹤0.01%	1374
2025 Q2	–	Sell	-32	Closed	-$1.07K	–	2381
2025 Q1	$1.07K	Buy	32 +17	+113%	+$635	﹤0.01%	2110
2024 Q4	$767	Buy	+15	New	+$839	﹤0.01%	2086
2024 Q3	–	Sell	-34	Closed	-$1.52K	–	2157
2024 Q2	$1.52K	Buy	+34	New	+$1.57K	﹤0.01%	1719
2022 Q1	–	Sell	-22	Closed	-$1K	–	1535
2021 Q4	$1K	Buy	+22	New	+$542	﹤0.01%	1195

Other funds holding CRNX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

MassMutual Private Wealth & Trust's CRNX Position: Q2 2026 in Review

MassMutual Private Wealth & Trust reduced its Crinetics Pharmaceuticals (CRNX) stake by 11% in Q2 2026, selling an estimated $929 and leaving 199 shares worth $7.45K. The position accounts for ﹤0.01% of the portfolio, ranked #1525.

MassMutual Private Wealth & Trust first reported a position in CRNX in Q4 2021 and has held it in 8 quarters since. The position peaked at $10.7K in Q3 2025. 57 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

MassMutual Private Wealth & Trust held 199 shares of Crinetics Pharmaceuticals worth $7.45K as of Q2 2026.
MassMutual Private Wealth & Trust sold 25 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $929.
Crinetics Pharmaceuticals made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q2 2026, its #1525 holding.
MassMutual Private Wealth & Trust first reported a position in Crinetics Pharmaceuticals in Q4 2021 and has held it in 8 quarters since.
MassMutual Private Wealth & Trust's Crinetics Pharmaceuticals position peaked at $10.7K in Q3 2025.
57 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.